BMS 303141

Cat. No. 4609 9 篇引用文献提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： ATP citrate lyase inhibitor; orally bioavailable

化学名： 3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide

纯度： ≥98% (HPLC)

引用文献 (9)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for BMS 303141

BMS 303141 is an ATP citrate lyase (ACL) inhibitor (IC₅₀ = 0.13 μM for human recombinant ACL); blocks lipid synthesis (IC₅₀ = 8 μM in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 μM. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia; reduces cell proliferation in HepG2 and Huh-7 cell lines and in PD-1 deficient lymphomas. Orally bioavailable.

技术数据 for BMS 303141

分子量	424.3
公式	C₁₉H₁₅Cl₂NO₄S
储存	Store at -20°C
纯度	≥98% (HPLC)
CAS Number	943962-47-8
PubChem ID	90488956
InChI Key	LIZVMVYXZWADCK-UHFFFAOYSA-N
Smiles	ClC1=CC(Cl)=C(O)C=C1S(NC2=C(C3=CC=CC=C3)C=CC(OC)=C2)(=O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for BMS 303141

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
	DMSO	4.24	10
	ethanol	21.21	50

制备储备液 for BMS 303141

以下数据基于产品分子量 424.3。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
0.5 mM	4.71 mL	23.57 mL	47.14 mL
2.5 mM	0.94 mL	4.71 mL	9.43 mL
5 mM	0.47 mL	2.36 mL	4.71 mL
25 mM	0.09 mL	0.47 mL	0.94 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for BMS 303141

分析证书/产品说明书

化学品安全技术说明书

参考文献 for BMS 303141

参考文献是支持产品生物活性的出版物。

Li et al (2007) 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg.Med.Chem.Lett. 17 3208 PMID: 17383874

Ma et al (2009) A novel direct homogeneous assay for ATP citrate lyase. J.Lipid Res. 50 2131 PMID: 19286649

Wartewig et al (2023) PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nat.Cancer 4 1508 PMID: 37723306

If you know of a relevant reference for BMS 303141, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 ATP Citrate Lyase Inhibitors

关键词: BMS 303141, BMS 303141 supplier, BMS303141, ATP, citrate, lyases, inhibits, inhibitors, plasma, glucose, triglycerides, orally, bioavailable, synthases, transferases, ACLY, immunometabolism, Citrate, Lyase, 4609, Tocris Bioscience